OUR TEAM.
Get to know the people behind Alv B.
CHRISTOFFER
J. FALCHENBERG
CEO
CEO
CHRISTOFFER J. FALCHENBERG
CEO
Christoffer er en entreprenør, med mange års erfaring som bedriftsleder. Christoffer er hovedansvarlig for Alv B og vil gi særlig fokus til forretningsutvikling. De siste årene har Christoffer jobbet med store digitaliserings og integrasjonsprosjekter på 'enterprise' nivå. Christoffer er, sammen med Biljana, ansvarlig for Alv B initiativet til Alv AS.
Christoffer er en entreprenør, med mange års erfaring som bedriftsleder. Christoffer er hovedansvarlig for Alv B og vil gi særlig fokus til forretningsutvikling. De siste årene har Christoffer jobbet med store digitaliserings og integrasjonsprosjekter på 'enterprise' nivå. Christoffer er, sammen med Biljana, ansvarlig for Alv B initiativet til Alv AS.
NANDA
TARTE
Head Quality Control
Head Quality Control
NANDA TARTE
Head Quality Control
Nanda has PhD in Biotechnology from Mumbai University with circa 18 years of experience in Academic Research and Pharmaceutical Industry. She has extensively worked in Developing, Preparing Risk Assessment and HSE documentation, standardizing, and evaluating Standard Operating procedures based on Quality standards with 5 years of experience in this field. Nanda has excellent knowledge of biotechnological laboratory equipment, and experience in cell biology, bioinformation, immunology, molecular biology, and microbiology, with a special focus on genetics, RNA/DNA technologies, Algal technology, and bioprocess-technologies. She has guided and supervised many undergraduate and post-graduate projects of research students with one winning prize at National level.
Nanda has PhD in Biotechnology from Mumbai University with circa 18 years of experience in Academic Research and Pharmaceutical Industry. She has extensively worked in Developing, Preparing Risk Assessment and HSE documentation, standardizing, and evaluating Standard Operating procedures based on Quality standards with 5 years of experience in this field. Nanda has excellent knowledge of biotechnological laboratory equipment, and experience in cell biology, bioinformation, immunology, molecular biology, and microbiology, with a special focus on genetics, RNA/DNA technologies, Algal technology, and bioprocess-technologies. She has guided and supervised many undergraduate and post-graduate projects of research students with one winning prize at National level.
JAKOB HØGH
GJELLESTAD
CHIEF MARKETING OFFICER
CHIEF MARKETING OFFICER
JAKOB HØGH GJELLESTAD
CHIEF MARKETING OFFICER
FRANCESCA
GATTI, PHD
COO
COO
FRANCESCA GATTI, PHD
COO
Francesca Gatti is an Industrial Scientist at ALV B. She is a molecular and cellular biologist with a PhD in Biotechnology with focus on immunology and biomaterials, from the University of Salento in collaboration with Harvard Medical School. Her academic research has been mostly in the areas of cell therapy, cell immuno-shielding with biomaterials, and immunotherapy for inflammatory and autoimmune diseases. She has worked in murine and non-human primate pre-clinical models, and GMP manufacturing for isolation of human cells in a clinical trial for cell therapy of type I diabetes. Francesca left academia in 2019 to be project leader in a start-up developing solutions for molecular diagnostics of infectious diseases and cancer. From 2021, as Industrial Scientist at ALV B, Francesca uses her know-how and expertise to develop, with the rest of the team, innovative treatments and diagnostic tools for solid cancers in dogs and cats.
Francesca Gatti is an Industrial Scientist at ALV B. She is a molecular and cellular biologist with a PhD in Biotechnology with focus on immunology and biomaterials, from the University of Salento in collaboration with Harvard Medical School. Her academic research has been mostly in the areas of cell therapy, cell immuno-shielding with biomaterials, and immunotherapy for inflammatory and autoimmune diseases. She has worked in murine and non-human primate pre-clinical models, and GMP manufacturing for isolation of human cells in a clinical trial for cell therapy of type I diabetes. Francesca left academia in 2019 to be project leader in a start-up developing solutions for molecular diagnostics of infectious diseases and cancer. From 2021, as Industrial Scientist at ALV B, Francesca uses her know-how and expertise to develop, with the rest of the team, innovative treatments and diagnostic tools for solid cancers in dogs and cats.
MIKAEL
KERBEOUF, PHD, DVM
R&D consultant
R&D consultant
MIKAEL KERBEOUF, PHD, DVM
R&D consultant
Mikael Kerboeuf is an R&D consultant for AlvB. He holds a degree in veterinary medicine from the Norwegian University of Life Sciences and is currently completing his PhD. Prior to embarking on his doctoral studies, Mikael gained clinical experience in private practice and at the University Small Animal Hospital, where he briefly oversaw the oncology department. His research is primarily centered on cancer metastasis and utilizing dogs as translational cancer models for human diseases. Specifically, his project investigates the involvement of tumour-associated macrophages in cancer and metastasis in dogs with bone cancer, in collaboration with the Roseline Institute at the University of Edinburgh and the Radium Hospital. Through his research, Mikael aims to identify novel immunotherapeutic targets that could benefit both humans and their canine companions.
Mikael Kerboeuf is an R&D consultant for AlvB. He holds a degree in veterinary medicine from the Norwegian University of Life Sciences and is currently completing his PhD. Prior to embarking on his doctoral studies, Mikael gained clinical experience in private practice and at the University Small Animal Hospital, where he briefly oversaw the oncology department. His research is primarily centered on cancer metastasis and utilizing dogs as translational cancer models for human diseases. Specifically, his project investigates the involvement of tumour-associated macrophages in cancer and metastasis in dogs with bone cancer, in collaboration with the Roseline Institute at the University of Edinburgh and the Radium Hospital. Through his research, Mikael aims to identify novel immunotherapeutic targets that could benefit both humans and their canine companions.
MARTE
FAUSKANGER
SENIOR SCIENTIST
SENIOR SCIENTIST
MARTE FAUSKANGER
SENIOR SCIENTIST
Marte is a molecular biologist with a PhD from the University of Oslo. She has been working at the Institute of Immunology at the Oslo University Hospital (Rikshospitalet) since 2012, with her main research area being tumor immunology. During her period as a master and PhD student she worked with murine models of hematological malignancies and melanoma. Marte has a particular interest in cancer immunotherapy and in the years after the PhD defense, she has been working with the development of CAR T cell therapies against solid tumors.
Marte is a molecular biologist with a PhD from the University of Oslo. She has been working at the Institute of Immunology at the Oslo University Hospital (Rikshospitalet) since 2012, with her main research area being tumor immunology. During her period as a master and PhD student she worked with murine models of hematological malignancies and melanoma. Marte has a particular interest in cancer immunotherapy and in the years after the PhD defense, she has been working with the development of CAR T cell therapies against solid tumors.
DAVID
KUNKE, PHD
ADVISORY BOARD MEMBER
ADVISORY BOARD MEMBER
DAVID KUNKE, PHD
ADVISORY BOARD MEMBER
LARS
MOE
HEAD OF CLINICAL DEVELOPMENT
HEAD OF CLINICAL DEVELOPMENT
LARS MOE
HEAD OF CLINICAL DEVELOPMENT
Lars Moe was trained as a veterinarian, and he has been working as a professor in internal medicine for small animals for many years. He has more than 40 years’ experience as a teacher, researcher, and leader in many aspects of veterinary science. His main research has been in clinical oncology, focusing on causation, including hereditary cancers, cancer epidemiology, diagnostics, and therapy. He was the rector at the Norwegian School of Veterinary Science for almost 10 years, and worked as head of the Department of Small Animal Clinical Sciences, Faculty of Life Sciences, University of Copenhagen, Denmark. He has a broad collaboration experience with Veterinary faculties in many countries and especially at the European level. In addition, Lars has had research collaborations with companies such as Nycomed GE Health, Pronova, and Algeta
Lars Moe was trained as a veterinarian, and he has been working as a professor in internal medicine for small animals for many years. He has more than 40 years’ experience as a teacher, researcher, and leader in many aspects of veterinary science. His main research has been in clinical oncology, focusing on causation, including hereditary cancers, cancer epidemiology, diagnostics, and therapy. He was the rector at the Norwegian School of Veterinary Science for almost 10 years, and worked as head of the Department of Small Animal Clinical Sciences, Faculty of Life Sciences, University of Copenhagen, Denmark. He has a broad collaboration experience with Veterinary faculties in many countries and especially at the European level. In addition, Lars has had research collaborations with companies such as Nycomed GE Health, Pronova, and Algeta
ANDRINE
M. LINDSETH
SENIOR ENGINEER
SENIOR ENGINEER
ANDRINE M. LINDSETH
SENIOR ENGINEER
Board of Directors
MARCUS SAHLIN
PETTERSEN
CHAIRMAN OF THE BOARD
CHAIRMAN OF THE BOARD
MARCUS SAHLIN PETTERSEN
CHAIRMAN OF THE BOARD
Christine
Bjerke
Member of the Board
Member of the Board
Christine Bjerke
Member of the Board
JOIN US
Through development of new treatment methods, research and data products will Alv B create value for our shareholders.
